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A B S T R A C T
A 66-year-old man was admitted for congestive heart failure with tachycardiac atrial ﬁbrillation (AF).
Heart failure was improved by diuretics, but control of heart rate by verapamil was insufﬁcient, and
bisoprolol was prescribed. After taking 2.5 mg of bisoprolol, he developed a general malaise followed by
sinus bradycardia and shock. In addition to catecholamines, the patient was treated with intra-aortic
balloon pumping and a pacemaker. With intensive therapy, the general condition was improved, and
acute elevation of liver enzymes after bisoprolol was normalized by the 17th hospital day. The blood
sample taken 30 h after the intake of bisoprolol showed abnormally high levels. Although the patient
was CYP2D6*10 heterozygote, the precise mechanism for excess accumulation of bisoprolol and
refractory shock remains unknown.
<Learning objective: Bisoprolol has been used for heart failure, but it may need caution to avoid
hemodynamic deterioration. In our case, refractory shock and acute liver injury were induced by
bisoprolol. The blood concentration was excessively high. The patient was CYP2D6*10 heterozygote, but
the precise mechanism and shock are to be studied.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The beneﬁcial long-term outcomes through bisoprolol have
been conﬁrmed in chronic heart failure (HF) [1], and the beneﬁcial
outcomes are related mainly to heart rate reduction [2,3].
Rapid atrial ﬁbrillation (AF) can be a cause of acute HF in
patients with preserved heart function [4], and control of heart rate
would be essential in them [5,6].
We experienced a case with severe refractory shock and
bradycardia which were induced by excessive accumulation of
bisoprolol given for the rate control of AF.
Case report
A 66-year-old male visited our hospital for suddenly developed
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsdyslipidemia, and AF. On physical examination, his blood pressure
was 160/80 mmHg. Coarse crackles were heard diffusely in both
lungs, but there was no evidence of neck vein distension or
peripheral edema.
His electrocardiogram (ECG) showed AF with a heart rate of
about 150 bpm and wide QRS complexes suggesting intraventric-
ular conduction delay (Fig. 1A). The chest X-ray revealed an
increased cardio-thoracic ratio to 57%, pulmonary congestion, and
pleural effusion (Fig. 2A). Echocardiography revealed a left
ventricle with end-systolic diameter 51 mm, and diffusely reduced
left ventricular wall motion with an ejection fraction of 25%.
Moderate regurgitation was observed in mitral, tricuspid, and
aortic valves. He was admitted for treatment of acute HF.
Complete blood cell counts showed a decrease in platelets
(12.3  104/mL). C-reactive protein was normal (0.28 mg/dl).
Lactic dihydrogenase (LDH = 355 U/L), alkaline phosphatase
(ALP = 257 U/L), and g-glutamyl transpeptidase (g-GTP = 76 U/L)
were mildly elevated. Creatine kinase and MB fraction were 242 U/L
and 20 ng/ml, respectively. Serum creatinine was 1.29 mg/dl with
estimated glomerular ﬁltration rate of 41.3 ml/m/1.73 m2.
After admission, diuretics (furosemide and eplerenone) and
verapamil were given, and dyspnea and pleural effusion were reserved.
Fig. 1.
Electrocardiograms. (A) Electrocardiogram on admission showed atrial ﬁbrillation with ventricular rate of 150 bpm. The wide QRS complexes and ST–T changes
were evident. (B) After bisoprolol, atrial ﬁbrillation was converted to normal sinus rhythm at 52 beats/min with prolonged PR interval (400 ms). ST depression is
evident in inferior and precordial leads.
Fig. 2.
The chest X ray and the coronary angiograms. (A) The heart was enlarged with pulmonary congestion. (B) Coronary angiography revealed total occlusion in the
proximal site of the right coronary artery, and about 75% stenosis in the left anterior descending artery. The collaterals to the right were well developed.
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room air, and the liver enzymes were normalized. In spite of
verapamil (120 mg/day), heart rate remained above 120 bpm, and
2.5 mg of bisoprolol was given on the 5th hospital day.
Heart rate decreased to 100 bpm, and then to 52 bpm with
sinus rhythm after bisoprolol (Fig. 1B). ECG showed a ﬁrst-degree
atrio-ventricular block and ST depression in inferior and precordial
leads. Within hours, he developed a general malaise. Blood
pressure declined to 104/72 mmHg, and by the next morning,
systolic blood pressure gradually fell to 74 mmHg, and the O2
saturation was 90% with room air.
Liver enzymes, alanine transaminase and aspartate transami-
nase elevated sharply again to 7700 U/L and 2600 U/L by the next
morning, and then to 21,933 U/L and 4727 U/L, respectively on the
7th day after taking bisoprolol (Fig. 2). Other enzymes were also
elevated: LDH = 16,821 U/L, ALP = 690 U/L, g-GTP = 124 U/L. Ab-
dominal computed tomography was negative for cholangiectasis
or biliary tract stone.
Systolic blood pressure remained low at 74 mmHg, and
catecholamines (dobutamine, dopamine, and noradrenaline) were
administered (Fig. 3). In addition, hemodyamics were supported by
intra-aortic balloon pumping (IABP) and bradycardia was treated
with a temporary pacemaker. At the time of insertion of IABP,
coronary angiography was performed and there was total
occlusion in the right and approximately 75% stenosis in the
distal left coronary artery (Fig. 2B). However, no intervention was
attempted because of good collateral circulation via septal
branches of left descending artery. Left ventriculography showed
a diffuse decrease in wall motion and depressed ejection fraction
to 27%. Pulmonary arterial pressure was 32 mmHg.Fig. 3.
The clinical course of the patient. After admission, diuretics
(furosemide and eplerenone) were given together with verapamil
which relieved symptoms of heart failure. Bisoprolol was given to
control ventricular rate further. Following a general malaise, the patient
developed shock that needed catecholamines (dopamine, dobutamine,
and noradrenaline) and IABP. The liver enzymes were elevated to peaks
on 7th day and returned to the normal levels with hemodynamic
improvement. bpm, beats per minute; IABP, intra-aortic balloon
pumping; LDH, lactic dehydrogenase; Cr, creatine kinase; ALT,
alanine transaminase; AST, aspartate transaminase.With intensive therapy, the circulatory state was improved, and
the liver enzymes normalized by the 17th hospital day (Fig. 3).
The ejection fraction of the left ventricle improved to 43% in
echocardiography. AF appeared within days and after full recovery,
he was discharged on the 30th day on verapamil (80 mg/day) and
digoxin (0.125 mg/day) with control of ventricular rate around
80 bpm (Fig. 3).
The blood concentration of bisoprolol was measured at 30 h
after taking the drug (2.5 mg), and was found to be excessively
high: 45.1 ng/ml. By the screening of CYP2D6 variants, he was
found to be CYP2D6*10 heterozygote.
Discussion
We experienced a case of acute HF. Although the patient had
coronary artery disease, HF was considered to be precipitated by
AF tachycardia. After addition of bisoprolol 2.5 mg for rate control,
he developed a general malaise followed by shock and liver injury.
The critical state was improved by intensive care that included
IABP and cardiac pacing. Excessively high blood level of bisoprolol
was conﬁrmed 30 h after intake. Although he was a heterozygote of
CYP2D6*10, the precise mechanisms of abnormal metabolism of
bisoprolol and refractory shock were not conﬁrmed.
Rapid AF can be one of the triggers of worsening of HF, and may
result in tachycardia-induced cardiomyopathy [4]. In such cases,
b-blocker is most effective for rate control followed by verapamil
and digoxin [5]. In the present patient, the coronary artery disease
was underlying, but verapamil was given ﬁrst to control heart rate
with insufﬁcient efﬁcacy. Then, bisoprolol was given cautiously at
a low dose (2.5 mg), and the patient fell into shock and needed
intensive care. The blood level of the drug was found to be
excessively high: 45.1 ng/ml. Bisoprolol is absorbed with bioavail-
ability >80% and peak plasma concentrations occur within 2–4 h.
Since the blood concentration of a single dose of 5 mg of bisoprolol
is reported to be 23.7 ng/ml at l3.1  0.41 h after oral administration
[7], the level of our patient was high.
Bisoprolol is known to be metabolized in the liver mainly via
CYP3A4 and CYP2D6 [6–10]. Our patient was a CYP2D6*10/1
heterozygote, but the functional impact of CYP2D6 allele is
substrate-dependent and the precise genotype–phenotype corre-
lation can be variable among b-blockers (Table 1) [6–10]. It is
unlikely that the CYP2D6 variant was the main cause of the high
concentration of bisoprolol [8,9], and preexisting HF, shock, mildly
impaired renal function, and/or excess responsiveness to the drug
agent might be involved for the abnormal metabolism of the drug.
Furthermore, prior administration of verapamil (120 mg/day)
which is metabolized by CYP3A4 might affect bisoprolol metabo-
lism [6]. Further attempts of genetic screening for CYP3A4 or
CYP2D6 are desired for optimal pharmacotherapy.
In summary, we had a patient with acute HF due to rapid
AF. Bisoprolol was given to control heart rate, but its blood
concentration elevated excessively resulting in refractory shock.Table 1 Main cardiac drugs metabolized by CYP2D6.
b-Blockers Timolol
Propranolol
Metoprolol
Alprenolol
Carvedilol
Bisoprolol
Antiarrhythmic Encainide
Flecainide
Mexiletine
Propafenone
Modiﬁed from reports [6–10].
The functional impact of CYP2D6 allele is substrate-dependent and the precise
genotype–phenotype correlation can be variable among b-blockers.
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not clear, and the precise cause of abnormal bisoprolol metabolism
and shock remains unknown.
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